Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has announced pivotal progress in its TSHA-102 gene therapy program for Rett ...

Learn how a new genetic therapy could transform treatment for rare ALS—keep reading for remarkable patient outcomes.

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...

Trial is evaluating VIPER-101, a novel, gene edited, autologous dual-population CAR-T therapy in patients with T-cell ...

Do you think lab rats "know" whether college students teaching them to run a maze care about and have confidence in them? The ...

This spring, the New York State legislature has an opportunity to confront an overlooked yet troubling aspect of its criminal legal system.

In addition to expanding fan-facing efforts, PepsiCo will also support the future of the sport through a new partnership with ...

FDA places clinical hold of RP-A501 for the treatment of patients with Danon disease due to a patient death. Click here to ...

Illumina Inc. today announced an expanded clinical oncology portfolio, unlocking the next new solutions to advance precision oncology and improve the standard of care. The company's broad range of ...

Scientists are making new discoveries every day, but many of them fall under the radar. Some of these findings are ...

Dark genome therapeutics market is poised for robust growth through 2035, driven by increasing demand for personalized medicine and genomic advances.